Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study

By King D.   Knapp M.   Thomas P.   Razzouk D.   Loze J.-Y.   Kan H.J.   van Baardewijk M.  

Current Medical Research and Opinion, Vol. 27, Iss. 2, 2011-02 ,pp. : 365-374

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data

By Rajagopalan Krithika  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 951-961

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK**

By Davies Andrew   Vardeva Kawitha   Loze Jean-Yves   L’’Italien Gilbert J.   Sennfalt Karin   Baardewijk Marc van  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3275-3285

Informa Healthcare

Access to resources Recommend Favorite

The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service

By Nazir J.   Hart W.M.  

Journal of Medical Economics, Vol. 17, Iss. 6, 2014-06 ,pp. : 408-414

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data

By Frey Simon   Linder Roland   Juckel Georg   Stargardt Tom  

The European Journal of Health Economics, Vol. 15, Iss. 2, 2014-03 ,pp. : 133-142

Springer Publishing Company

Access to resources Recommend Favorite